Data Published in The Red Journal Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial

... | May 2, 2023

Related Keywords

California ,United States ,South San Francisco ,Elai Davicioni ,Daniel Spratt ,Vincentk Smith ,National Cancer ,National Comprehensive Cancer Network ,Nasdaq ,Veracyte Inc ,Twitter ,International Journal Of Radiation Oncology ,International Journal ,Radiation Oncology ,Decipher Prostate Genomic Classifier ,Decipher Prostate ,University Hospitals Seidman Cancer Center ,Case Western Reserve University School ,Prostate Cancer ,Cancer Institute Sponsored ,Annual Report ,Quarterly Report ,Nanostring Technologies ,Veracyte ,Nc Stock Exchange ,News ,Information ,Press Release ,Findings ,Epresent ,First ,Validation ,F ,Many ,Gene ,Expression ,Biomarker ,Or ,Patients ,Sing ,Data ,Rom ,Randomized ,Hase , ,Linical Vcyt Us92337f1075 ,